Page last updated: 2024-09-03

gefitinib and Cholangiocarcinoma

gefitinib has been researched along with Cholangiocarcinoma in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aoudjehane, L; Clapéron, A; Conti, F; Desbois-Mouthon, C; Firrincieli, D; Fouassier, L; Ho-Bouldoires, TH; Housset, C; Merabtene, F; Mergey, M; Prignon, A; Scatton, O; Wendum, D1
Chang, VH; Chen, CC; Jiang, X; Lin, HY; Liu, YR; Wang, J; Yang, SH; Yen, Y; Zhang, K1
Egawa, S; Katayose, Y; Mizuma, M; Motoi, F; Oda, A; Ohtuska, H; Oikawa, M; Onogawa, T; Rikiyama, T; Sasaki, T; Shirasou, S; Unno, M; Yabuuchi, S; Yamamoto, K; Yoshida, H1
Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H1
Bronk, SF; Gores, GJ; Gwak, GY; Lee, HS; Werneburg, NW; Yoon, JH1
Altiok, S; Amador, ML; Chan, A; Hidalgo, M; Jimeno, A; Maitra, A; Mezzadra, H; Nielsen, ME; Patel, P1
Blüthner, T; Caca, K; Feisthammel, J; Kamenz, T; Kluge, A; Mössner, J; Tannapfel, A; Wiedmann, M1

Other Studies

7 other study(ies) available for gefitinib and Cholangiocarcinoma

ArticleYear
Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor.
    Hepatology (Baltimore, Md.), 2013, Volume: 58, Issue:6

    Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Disease Progression; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Mice; Myofibroblasts; Quinazolines; Signal Transduction; Stromal Cells

2013
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
    Oncotarget, 2015, Sep-15, Volume: 6, Issue:27

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Protein Serine-Threonine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays

2015
ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines.
    Anticancer research, 2009, Volume: 29, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Cycle; Cell Proliferation; Cholangiocarcinoma; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Quinazolines; Radiation Tolerance; Tumor Cells, Cultured; X-Rays

2009
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
    Anticancer research, 2012, Volume: 32, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays

2012
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.
    Journal of hepatology, 2004, Volume: 41, Issue:5

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Cyclooxygenase 2; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Membrane Proteins; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Quinazolines; Signal Transduction; Tyrphostins; Ubiquitin

2004
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:7

    Topics: Animals; Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy, Fine-Needle; Cholangiocarcinoma; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Signal Transduction

2006
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Anti-cancer drugs, 2006, Volume: 17, Issue:7

    Topics: Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; DNA, Complementary; DNA, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Purines; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2

2006